Physician profile
Robert Skinner
NPI 1558363689
$9,234.13
in general payments reported to CMS, 2019-2025
50 companies · $1,206 in 2025
The $1,206 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,299 · 2020: $332 · 2021: $718 · 2022: $1,892 · 2023: $1,549 · 2024: $1,240 · 2025: $1,206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,982 · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,982.24 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,417.97 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,197.01 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,181.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,003.11 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $602.31 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $527.72 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $453.08 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $381.52 | 2019-2025 | Capvaxive, Gardasil 9 |
| Amgen INC. | $324.77 | 2019-2025 | Repatha, Otezla, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $320.44 | 2019-2024 | Trintellix |
| Kowa Pharmaceuticals America, INC. | $177.05 | 2019-2023 | Seglentis |
| Bayer Healthcare Pharmaceuticals INC. | $154.17 | 2022-2025 | |
| Abbott Laboratories | $152.40 | 2021-2023 | Freestyle Libre 2, Freestyle Libre, Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $144.70 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Biohaven Pharmaceutical Holding Company LTD. | $127.69 | 2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Skinner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.